Lexaria Updates Current GLP-1 Market
Lexaria Bioscience Corp. (NASDAQ:LEXX) provides an update on the rapidly growing GLP-1 receptor agonist market. The market has expanded from less than $4 billion in 2020 to a projected $44.5-$49.3 billion in 2024, with analysts forecasting up to $471.1 billion by 2033. Currently, over 95% of the market is dominated by two drugs: semaglutide and tirzepatide. The oral tablet form of these drugs, which currently comprises only 10% of the market, is expected to grow significantly.
Lexaria's DehydraTECH drug delivery system aims to lead in oral GLP-1/GIP drug delivery. Recent studies have shown GLP-1 drugs' potential in reducing cardiovascular risks and improving outcomes for chronic kidney disease patients, suggesting possible expanded therapeutic applications in the future.
Lexaria Bioscience Corp. (NASDAQ:LEXX) fornisce un aggiornamento sul mercato in rapida crescita degli agonisti dei recettori GLP-1. Il mercato è passato da meno di 4 miliardi di dollari nel 2020 a una stima di 44,5-49,3 miliardi di dollari nel 2024, con analisti che prevedono fino a 471,1 miliardi di dollari entro il 2033. Attualmente, oltre il 95% del mercato è dominato da due farmaci: semaglutide e tirzepatide. La forma di compressa orale di questi farmaci, che attualmente rappresenta solo il 10% del mercato, è prevista in forte crescita.
Il sistema di somministrazione di farmaci DehydraTECH di Lexaria mira a diventare leader nella somministrazione orale di farmaci GLP-1/GIP. Studi recenti hanno dimostrato il potenziale dei farmaci GLP-1 nel ridurre i rischi cardiovascolari e nel migliorare gli esiti per i pazienti affetti da malattie renali croniche, suggerendo possibili applicazioni terapeutiche ampliabili in futuro.
Lexaria Bioscience Corp. (NASDAQ:LEXX) proporciona una actualización sobre el mercado de agonistas del receptor GLP-1, que está en rápido crecimiento. El mercado ha aumentado de menos de 4 mil millones de dólares en 2020 a un proyectado 44,5-49,3 mil millones de dólares en 2024, con analistas pronosticando hasta 471,1 mil millones de dólares para 2033. Actualmente, más del 95% del mercado está dominado por dos medicamentos: semaglutida y tirzepatida. La forma de tableta oral de estos medicamentos, que actualmente representa solo el 10% del mercado, se espera que crezca significativamente.
El sistema de administración de medicamentos DehydraTECH de Lexaria tiene como objetivo liderar la administración oral de medicamentos GLP-1/GIP. Estudios recientes han mostrado el potencial de los medicamentos GLP-1 para reducir los riesgos cardiovasculares y mejorar los resultados en pacientes con enfermedad renal crónica, sugiriendo posibles aplicaciones terapéuticas ampliadas en el futuro.
렉사리아 바이오사이언스 주식회사(NASDAQ:LEXX)는 급성장 중인 GLP-1 수용체 작용제 시장에 대한 업데이트를 제공합니다. 시장은 2020년 40억 달러 미만에서 2024년에는 445억-493억 달러로 예상되며, 분석가들은 2033년까지 4711억 달러에 이를 것으로 예측하고 있습니다. 현재 95% 이상의 시장이 두 가지 약물인 세마글루타이드와 티르제파타이드에 의해 지배되고 있습니다. 이들 약물의 경구 정제 형태는 현재 시장 점유율 10%을 차지하고 있으며, 큰 폭의 성장이 예상됩니다.
렉사리아의 DehydraTECH 약물 전달 시스템은 경구 GLP-1/GIP 약물 전달 분야에서 선도하는 것을 목표로 합니다. 최근 연구에 따르면 GLP-1 약물은 심혈관 위험을 줄이고 만성신장병 환자의 결과를 개선하는 데 잠재력이 있으며, 이는 향후 가능한 치료 응용의 확대를 시사합니다.
Lexaria Bioscience Corp. (NASDAQ:LEXX) fournit une mise à jour sur le marché en forte croissance des agonistes des récepteurs GLP-1. Le marché est passé de moins de 4 milliards de dollars en 2020 à une prévision de 44,5 à 49,3 milliards de dollars en 2024, les analystes prévoyant jusqu'à 471,1 milliards de dollars d'ici 2033. Actuellement, plus de 95% du marché est dominé par deux médicaments : sémaglutide et tirzepatide. La forme de comprimé oral de ces médicaments, qui ne représente actuellement que 10% du marché, devrait connaître une croissance significative.
Le système de délivrance de médicaments DehydraTECH de Lexaria vise à devenir le leader dans la délivrance orale de médicaments GLP-1/GIP. Des études récentes ont montré le potentiel des médicaments GLP-1 à réduire les risques cardiovasculaires et à améliorer les résultats pour les patients atteints de maladies rénales chroniques, suggérant des applications thérapeutiques élargies possibles à l'avenir.
Die Lexaria Bioscience Corp. (NASDAQ:LEXX) gibt ein Update zum rasant wachsenden Markt der GLP-1-Rezeptor-Agonisten. Der Markt ist von weniger als 4 Milliarden Dollar im Jahr 2020 auf eine prognostizierte 44,5-49,3 Milliarden Dollar im Jahr 2024 gewachsen, wobei Analysten bis zu 471,1 Milliarden Dollar bis 2033 vorhersagen. Derzeit wird über 95% des Marktes von zwei Medikamenten dominiert: Semaglutid und Tirzepatid. Die orale Tablettenform dieser Medikamente, die derzeit nur 10% des Marktes ausmacht, wird voraussichtlich erheblich wachsen.
Das DehydraTECH-Drug-Delivery-System von Lexaria zielt darauf ab, im Bereich der oralen GLP-1/GIP-Arzneimittelverabreichung führend zu sein. Neueste Studien haben das Potenzial von GLP-1-Arzneimitteln zur Reduzierung kardiovaskulärer Risiken und zur Verbesserung der Ergebnisse bei Patienten mit chronischer Nierenerkrankung gezeigt, was mögliche erweiterte therapeutische Anwendungen in der Zukunft vorschlägt.
- Rapid market growth: GLP-1 market projected to reach $44.5-$49.3 billion in 2024, up from less than $4 billion in 2020
- Lexaria's DehydraTECH system shows potential to improve drug delivery kinetics and blood sugar control with semaglutide
- Expanding applications for GLP-1 drugs, including cardiovascular and kidney disease treatments, could lead to market growth beyond current projections
- Oral tablet form of GLP-1 drugs expected to grow significantly from current 10% market share
- Highly competitive market with over 95% dominated by two major pharmaceutical companies
- Lexaria's technology not yet approved or widely adopted in the GLP-1 market
Insights
The GLP-1 market is experiencing explosive growth, with revenues for leading drugs semaglutide and tirzepatide reaching
- Increasing FDA approvals for new indications (e.g., cardiovascular risk reduction)
- Growing evidence of benefits for chronic kidney disease and other conditions
- Potential for oral formulations to capture market share from injectables
Lexaria's DehydraTECH technology could position the company to capitalize on the shift towards oral GLP-1 drugs, which currently represent only
The expanding therapeutic applications of GLP-1 drugs beyond weight loss and diabetes control are particularly noteworthy:
- Cardiovascular benefits:
20% reduction in major cardiovascular events - Chronic kidney disease: Improved outcomes and lower mortality rates
- Potential neuroprotective effects through brain-mediated inflammation reduction
These findings suggest a broader patient population could benefit from GLP-1 therapies, potentially expanding the market further. Lexaria's DehydraTECH system, if proven effective for oral GLP-1 delivery, could address a significant unmet need. The company's preliminary data showing improved drug delivery kinetics and blood sugar control with semaglutide is promising. However, rigorous clinical trials and regulatory approvals will be important for Lexaria to compete in this rapidly evolving market dominated by pharmaceutical giants.
KELOWNA, BC / ACCESSWIRE / October 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, provides an update on recent glucagon-like peptide-1 ("GLP-1") receptor agonist market sector advancements.
In 2020 the total market size for GLP-1 drugs was less than
Today, the GLP-1 market is growing faster than nearly all historic forecasts had predicted. Bay Bridge Bio has published a useful interactive chart which highlights that, while there are a number of GLP-1 drug brands available today, over
Despite this unprecedented growth, GLP-1/GIP drugs currently delivered by oral tablet comprise only roughly
Analysts around the world have been trying to keep up with GLP-1 trends. Compounding the difficulty in doing so is projecting which major pharmaceutical firms will achieve approval for GLP-1/GIP and related drugs currently in the development pipeline. Tirzepatide, for example, was only approved by the FDA in May, 2022, but Eli Lilly is forecasting
Analyst Firm | Link to Report |
| 2023 |
| 2024 |
| 2030 |
| 2031 |
|
| 2032 Billions $USD |
| 2033+ |
| |||||
ResearchAndMarkets |
|
|
| $ | 28.1 |
| $ | 133.4 |
|
|
|
|
|
|
| |||||
InsightAce Analytic |
| $ | 44.5 |
|
|
|
|
|
|
| $ | 95.4 |
|
|
|
|
| |||
BMO Capital Markets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| $ | 150.0 |
| ||
J.P. Morgan |
|
|
|
|
|
|
| $ | 100.0 |
|
|
|
|
|
|
|
|
| ||
Roots Analysis |
|
|
|
| $ | 49.3 |
|
|
|
|
|
|
|
|
| $ | 157.5 |
| ||
Global Data |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| $ | 125.0 |
| ||
UBS |
|
|
|
|
|
|
| $ | 126.0 |
|
|
|
|
|
|
|
|
| ||
Goldman Sachs |
|
|
|
|
|
|
| $ | 130.0 |
|
|
|
|
|
|
|
|
| ||
MarketsAndMarkets |
|
|
|
| $ | 47.4 |
|
|
|
|
|
|
| $ | 471.1 |
|
|
|
| |
Expanding Applications For GLP-1 Drugs
The effects of GLP-1 drugs for weight loss and diabetes control are well known, but additional benefits are appearing outside of those original areas of investigation. For example, on March 8, 2024, the FDA approved Wegovy ® (semaglutide) "to reduce the risk of cardiovascular death, heart attack and stroke". A large study of 17,600 people evidenced that weekly semaglutide injections reduced those cardiovascular risks by ~
Heart disease remains the #1 leading cause of death in America, resulting in 702,880 deaths in 2022 . The World Health Organization estimates that cardiovascular diseases cause 17.9 million deaths , globally, each year.
A meta-analysis of 12 studies that included ~73,000 patients has shown reduced harm experienced from chronic kidney disease when GLP-1 drugs were administered. In a large analysis of over 165,000 patients , type-2 diabetic patients with acute kidney disease receiving GLP-1 drugs evidenced lower mortality rates and lower incidences of both major cardiovascular events and major adverse kidney events, than those patients not receiving GLP-1 drugs.
Approximately 35 million people in the US have chronic kidney disease , according to the Center for Disease Control, and it is estimated that 1.2 million people around the world die each year from the disease.
Some of the latest research seems to indicate a connection between GLP-1 drugs and the human brain, wherein inflammation models including heart disease, atherosclerosis, and liver and kidney inflammation may be mediated through the brain.
Given that heart disease and kidney disease are so widespread, and with the latest analytical study data showing that GLP-1 drugs are improving health outcomes for patients with these diseases, it seems likely that, over time, GLP-1 drugs may be approved for additional therapeutic uses in patient populations that far exceed today's regulator-approved disease indications.
GLP-1/GIP and related drugs are already one of the fastest growing sectors in the history of the pharmaceutical industry. Given that these drugs are evidencing an expansion of their therapeutic applications and are expected to be approved by national drug regulators for expanded use; and given that health insurers are increasing their coverage for these drugs, it seems possible that current growth expectations of most analysts are conservative.
Lexaria has already provided evidence that DehydraTECH seems to provide improved drug delivery kinetics and improved blood sugar control with the world's leading GLP-1 drug: semaglutide. Lexaria's interest and focus on the GLP-1/GIP and related drug sector will continue for the foreseeable future with additional studies and evaluation.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on accesswire.com
FAQ
What is the projected market size for GLP-1 drugs in 2024 according to the Lexaria (LEXX) press release?
How much of the current GLP-1 market is served by oral tablet forms, as mentioned in the Lexaria (LEXX) update?
What potential new applications for GLP-1 drugs are mentioned in the Lexaria (LEXX) market update?
How has Lexaria's (LEXX) DehydraTECH system performed with semaglutide according to the press release?
